Cue Health Inc. (HLTH) Prices 12.5M Share IPO at $16/sh

Cue Health Inc. (Nasdaq: HLTH), a health technology company, today announced the pricing of its initial public offering of 12,500,000 shares of its common stock at a public offering price of $16.00 per share, for gross proceeds of $200.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Cue Health. All of the shares are being offered and sold by Cue Health. Cue Health's common stock is expected to begin trading on the Nasdaq Global Select Market on September 24, 2021 under the ticker symbol "HLTH." The offering is expected to close on September 28, 2021, subject to the satisfaction of customary closing conditions. In addition, Cue Health has granted the underwriters a 30-day option to purchase up to 1,875,000 additional shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, and Cowen and Company, LLC are acting as lead bookrunners for the offering. BTIG, LLC is acting as lead manager for the offering.

A registration statement relating to the offering of these securities was declared effective by the Securities and Exchange Commission (the "SEC") on September 23, 2021. Copies of the registration statement can be accessed by visiting the SEC website at www.sec.gov. The securities referred to in this release are to be offered only by means of a prospectus. A preliminary prospectus describing the terms of the offering has been filed with the SEC and forms a part of the effective registration statement. When available, a copy of the final prospectus relating to the offering may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at [email protected]; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at [email protected]; and Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by telephone at (833) 297-2926, or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

You May Also Be Interested In

• Biohaven Pharma (BHVN) Prices 5.6M Share Offering at $41/sh
• Rubrik IPO: 5 key things to know
• Benitec Biopharma (BNTC) Announces $40M Placement at $4.80/sh